vs
Side-by-side financial comparison of Emerald Holding, Inc. (EEX) and Esperion Therapeutics, Inc. (ESPR). Click either name above to swap in a different company.
Esperion Therapeutics, Inc. is the larger business by last-quarter revenue ($168.4M vs $132.7M, roughly 1.3× Emerald Holding, Inc.). On growth, Esperion Therapeutics, Inc. posted the faster year-over-year revenue change (143.7% vs 24.3%). Over the past eight quarters, Esperion Therapeutics, Inc.'s revenue compounded faster (10.6% CAGR vs -0.3%).
TVS Emerald Haven Realty Limited is an Indian real estate development company headquartered in Chennai, Tamil Nadu. A subsidiary of TVS Holdings, it specializes in sustainable residential communities and urban development projects.
Esperion Therapeutics, Inc. is a publicly traded American pharmaceutical company focused on the development of bempedoic acid, an orally available small molecule designed to lower elevated levels of LDL-C. The company is headquartered in Ann Arbor, Michigan.
EEX vs ESPR — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $132.7M | $168.4M |
| Net Profit | $-30.2M | — |
| Gross Margin | — | — |
| Operating Margin | -11.8% | 50.6% |
| Net Margin | -22.8% | — |
| Revenue YoY | 24.3% | 143.7% |
| Net Profit YoY | -692.2% | — |
| EPS (diluted) | $-0.15 | $0.32 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $132.7M | $168.4M | ||
| Q3 25 | $77.5M | $87.3M | ||
| Q2 25 | $105.5M | $82.4M | ||
| Q1 25 | $147.7M | $65.0M | ||
| Q4 24 | $106.8M | $69.1M | ||
| Q3 24 | $72.6M | $51.6M | ||
| Q2 24 | $86.0M | $73.8M | ||
| Q1 24 | $133.4M | $137.7M |
| Q4 25 | $-30.2M | — | ||
| Q3 25 | $-14.4M | $-31.3M | ||
| Q2 25 | $-1.4M | $-12.7M | ||
| Q1 25 | $15.3M | $-40.5M | ||
| Q4 24 | $5.1M | — | ||
| Q3 24 | $-11.1M | $-29.5M | ||
| Q2 24 | $-2.8M | $-61.9M | ||
| Q1 24 | $11.0M | $61.0M |
| Q4 25 | -11.8% | 50.6% | ||
| Q3 25 | -10.1% | -11.4% | ||
| Q2 25 | 9.7% | 8.6% | ||
| Q1 25 | 24.2% | -34.0% | ||
| Q4 24 | 19.5% | -6.4% | ||
| Q3 24 | -6.5% | -31.0% | ||
| Q2 24 | 7.4% | 3.5% | ||
| Q1 24 | 18.2% | 52.5% |
| Q4 25 | -22.8% | — | ||
| Q3 25 | -18.6% | -35.9% | ||
| Q2 25 | -1.3% | -15.4% | ||
| Q1 25 | 10.4% | -62.2% | ||
| Q4 24 | 4.8% | — | ||
| Q3 24 | -15.3% | -57.2% | ||
| Q2 24 | -3.3% | -83.9% | ||
| Q1 24 | 8.2% | 44.3% |
| Q4 25 | $-0.15 | $0.32 | ||
| Q3 25 | $-0.07 | $-0.16 | ||
| Q2 25 | $-0.01 | $-0.06 | ||
| Q1 25 | $0.08 | $-0.21 | ||
| Q4 24 | $0.01 | $-0.14 | ||
| Q3 24 | $-0.05 | $-0.15 | ||
| Q2 24 | $-0.03 | $-0.33 | ||
| Q1 24 | $0.00 | $0.34 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $100.9M | $167.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $338.8M | $-302.0M |
| Total Assets | $1.2B | $465.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $100.9M | $167.9M | ||
| Q3 25 | $95.4M | $92.4M | ||
| Q2 25 | $156.4M | $86.1M | ||
| Q1 25 | $276.8M | $114.6M | ||
| Q4 24 | $194.8M | $144.8M | ||
| Q3 24 | $188.9M | $144.7M | ||
| Q2 24 | $193.2M | $189.3M | ||
| Q1 24 | $186.8M | $226.6M |
| Q4 25 | $338.8M | $-302.0M | ||
| Q3 25 | $369.5M | $-451.4M | ||
| Q2 25 | $389.4M | $-433.5M | ||
| Q1 25 | $392.1M | $-426.2M | ||
| Q4 24 | $385.9M | $-388.7M | ||
| Q3 24 | $391.1M | $-370.2M | ||
| Q2 24 | $407.6M | $-344.2M | ||
| Q1 24 | $-90.7M | $-294.3M |
| Q4 25 | $1.2B | $465.9M | ||
| Q3 25 | $1.2B | $364.0M | ||
| Q2 25 | $1.2B | $347.1M | ||
| Q1 25 | $1.2B | $324.0M | ||
| Q4 24 | $1.0B | $343.8M | ||
| Q3 24 | $1.1B | $314.1M | ||
| Q2 24 | $1.1B | $352.3M | ||
| Q1 24 | $1.1B | $373.1M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $12.3M | $45.2M |
| Free Cash FlowOCF − Capex | $11.7M | — |
| FCF MarginFCF / Revenue | 8.8% | — |
| Capex IntensityCapex / Revenue | 0.5% | 0.0% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $41.4M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $12.3M | $45.2M | ||
| Q3 25 | $1.8M | $-4.3M | ||
| Q2 25 | $15.9M | $-31.4M | ||
| Q1 25 | $12.6M | $-22.6M | ||
| Q4 24 | $20.6M | $-35.0M | ||
| Q3 24 | $9.1M | $-35.3M | ||
| Q2 24 | $9.8M | $-7.2M | ||
| Q1 24 | $7.3M | $53.8M |
| Q4 25 | $11.7M | — | ||
| Q3 25 | $1.5M | — | ||
| Q2 25 | $15.8M | — | ||
| Q1 25 | $12.4M | — | ||
| Q4 24 | $19.9M | — | ||
| Q3 24 | $9.0M | $-35.5M | ||
| Q2 24 | $9.6M | $-7.3M | ||
| Q1 24 | $7.0M | $53.8M |
| Q4 25 | 8.8% | — | ||
| Q3 25 | 1.9% | — | ||
| Q2 25 | 15.0% | — | ||
| Q1 25 | 8.4% | — | ||
| Q4 24 | 18.6% | — | ||
| Q3 24 | 12.4% | -68.7% | ||
| Q2 24 | 11.2% | -9.9% | ||
| Q1 24 | 5.2% | 39.0% |
| Q4 25 | 0.5% | 0.0% | ||
| Q3 25 | 0.4% | 0.0% | ||
| Q2 25 | 0.1% | 0.0% | ||
| Q1 25 | 0.1% | 0.0% | ||
| Q4 24 | 0.7% | 0.0% | ||
| Q3 24 | 0.1% | 0.3% | ||
| Q2 24 | 0.2% | 0.1% | ||
| Q1 24 | 0.2% | 0.1% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 0.82× | — | ||
| Q4 24 | 4.04× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 0.66× | 0.88× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
EEX
| Connections Segment | $121.9M | 92% |
| Commerce Segment | $5.5M | 4% |
| Content | $5.3M | 4% |
ESPR
| Collaboration Revenue | $124.7M | 74% |
| Products | $43.7M | 26% |
